Trade Mark Journal No.2026/030 24 July 2026

UK00004417738 17 July 2026 (5,44)

Class 5: Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alcohol use disorder, alopecia, Alzheimer's disease, asthma, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, cancer, cardiovascular disease, central nervous system diseases and disorders, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, obstructive sleep apnea, osteoarthritis, pain, Parkinson's disease, psoriasis, psoriatic arthritis, retinal disease, rheumatoid arthritis, ulcerative colitis, vascular diseases and vision loss; pharmaceutical preparations for weight management.
Class 44: Medical information services in the field of cancer.

Eli Lilly and Company

Representative: Page, White & Farrer Limited